Conserving nature's stage provides a foundation for safeguarding both geodiversity and biodiversity in protected and conserved areas

This article outlines the fundamental connections between geodiversity and biodiversity by providing a geoconservation perspective on the concept of 'conserving nature's stage' as a basis for safeguarding both geodiversity and biodiversity in the face of environmental and climate change. Conserving nature's stage – the physical environment in which species exist – provides a means of developing more integrated approaches to nature conservation, delivering benefits for both geodiversity and biodiversity conservation, and incorporating key principles of geoconservation in the management of protected and conserved areas.Publisher PDFPeer reviewe

The status and future of essential geodiversity variables

Rapid environmental change, natural resource overconsumption and increasing concerns about ecological sustainability have led to the development of 'Essential Variables' (EVs). EVs are harmonized data products to inform policy and to enable effective management of natural resources by monitoring global changes. Recent years have seen the instigation of new EVs beyond those established for climate, oceans and biodiversity (ECVs, EOVs and EBVs), including Essential Geodiversity Variables (EGVs). EGVs aim to consistently quantify and monitor heterogeneity of Earth-surface and subsurface abiotic features, including geology, geomorphology, hydrology and pedology. Here we assess the status and future development of EGVs to better incorporate geodiversity into policy and sustainable management of natural resources. Getting EGVs operational requires better consensus on defining geodiversity, investments into a governance structure and open platform for curating the development of EGVs, advances in harmonizing in situ measurements and linking heterogeneous databases, and development of open and accessible computational workflows for global digital mapping using machine-learning techniques. Cross-disciplinary collaboration and partnerships with governmental and private organizations are needed to ensure the successful development and uptake of EGVs across science and policy. This article is part of the Theo Murphy meeting issue 'Geodiversity for science and society'

A reply to ‘A meta-database of Holocene sediment cores for England: missing data’ (Tooley 2015)

We welcome the response of Tooley (2015) to our article describing a new meta-database of Holocene sediment cores for England. In our article we describe the online publication of this meta-database, arising from systematic meta-search. We define its scope and the meta-data it contains, before providing the data themselves (in the Electronic Supplementary Material online). We note that Prof. Tooley describes the idea of such a database as important and valuable, and we welcome the constructive approach he adopts throughout his article

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Conserving nature's stage provides a foundation for safeguarding both geodiversity and biodiversity in protected and conserved areas

This article outlines the fundamental connections between geodiversity and biodiversity by providing a geoconservation perspective on the concept of 'conserving nature's stage' as a basis for safeguarding both geodiversity and biodiversity in the face of environmental and climate change. Conserving nature's stage – the physical environment in which species exist – provides a means of developing more integrated approaches to nature conservation, delivering benefits for both geodiversity and biodiversity conservation, and incorporating key principles of geoconservation in the management of protected and conserved areas

Geodiversity Action Plans – A method to facilitate, structure, inform and record action for geodiversity.

Geodiversity Action Plans are used widely within the United Kingdom to inform and record action for geodiversity and geoconservation. They encompass both site-based audit and conservation with a wider perspective on geodiversity resources available in an agreed area (such as geological sites, museum collections and building stones) with ambitions to present and communicate, influence policy and practice, and to secure resources in relation to geodiversity. Geodiversity Action Plans (GAPs) are used particularly at local and company level to focus and highlight the work needed to be carried out and a as key mechanism to facilitate and support the delivery of the overarching UK Geodiversity Action Plan (UKGAP). Importantly, GAPs cross cut interests and are multidisciplinary. Although they are mainly a UK tool for geoconservation the principles and approach are easily transferred and could be duplicated in other countries

Geodiversity Action Plans – A method to facilitate, structure, inform and record action for geodiversity

Geodiversity Action Plans are used widely within the United Kingdom to inform and record action for geodiversity and geoconservation. They encompass both site-based audit and conservation with a wider perspective on geodiversity resources available in an agreed area (such as geological sites, museum collections and building stones) with ambitions to present and communicate, influence policy and practice, and to secure resources in relation to geodiversity. Geodiversity Action Plans (GAPs) are used particularly at local and company level to focus and highlight the work needed to be carried out and a as key mechanism to facilitate and support the delivery of the overarching UK Geodiversity Action Plan (UKGAP). Importantly, GAPs cross cut interests and are multidisciplinary. Although they are mainly a UK tool for geoconservation the principles and approach are easily transferred and could be duplicated in other countries

Conserving nature’s stage provides a foundation for safeguarding both geodiversity and biodiversity in protected and conserved areas

This article outlines the fundamental connections between geodiversity and biodiversity by providing a geoconservation perspective on the concept of “conserving nature’s stage” as a basis for safeguarding both geodiversity and biodiversity in the face of environmental and climate change. Conserving nature’s stage—the physical environment in which species exist—provides a means of developing more integrated approaches to nature conservation, delivering benefits for both geodiversity and biodiversity conservation, and incorporating key principles of geoconservation in the management of protected and conserved areas